Former Investor Who Chose Broadcasting Over Biotech ETFs

Pathfinders in Biopharma

39:50

The truth is out West! We’re hopping on the ET Highway and venturing to the most notorious alien hot spots, including Roswell’s infamous crash site, Area 51’s eerie perimeter, and a mysterious desert watchtower. Join us as journalist Laura Krantz, host of the podcast Wild Thing , beams up to share stories from the front lines of UFO reporting—from strange sightings and quirky festivals to a mailbox where people leave letters to extraterrestrials. Maybe you’ll even decide for yourself: Is Earth a tourist stop for spaceships? UFO hot spots you’ll encounter in this episode: - UFO Watchtower (near Great Sand Dunes National Park, Colorado) - Roswell, New Mexico - Area 51, Nevada - Extraterrestrial Highway (aka State Route 375), Nevada - Little A’Le’Inn, ET Highway, Nevada - E.T. Fresh Jerky, ET Highway, Nevada - Alien Research Center, ET Highway, Nevada - The Black Mailbox, ET Highway, Nevada Via Podcast is a production of AAA Mountain West Group .…

рік тому 11:46

MP3•Головна епізоду

Former biotech investor, Brad Loncar has pivoted his career from investing to reporting on the industry. Instead of serving the biotech bubble, he hopes to reach a wide audience with interest in science. Loncar explains why he switched careers and sets out his ambitions for his channel, Biotech TV.

47 епізодів

Former Investor Who Chose Broadcasting Over Biotech ETFs

Pathfinders in Biopharma

published рік тому

Поширити

MP3•Головна епізоду

47 епізодів

Усі епізоди

1
BioAge is translating insights from the science of aging into new medicines 19:32

8 днів тому19:32

19:32

Scott Neidhold, Director in RBC’s Life Sciences Investment Banking Practice, sits down with Kristen Fortney, CEO and Co-Founder of BioAge, for a deep dive into how her company is turning cutting-edge aging science into real therapeutic breakthroughs — and what it means for the future of biopharma.

1
Uncertainty reigns, but opportunity persists for biotech’s 2025 9:17

17 weeks тому9:17

9:17

Universal wisdom had it that a Republican sweep in the U.S. election would favor biotech. Appointments to the new administration’s healthcare leadership make that far less certain. What effect will this and other factors have on the industry in 2025, and where are the breakthroughs likely to be found? Brian Abrahams, Head of Global Healthcare Research at RBC Capital Markets, looks ahead with in this episode of Pathfinders in Biotech.…

1
Unlocking Biotech’s Potential: Strategies for Navigating Public and Private Market Investments 22:38

28 weeks тому22:38

22:38

Innovation is surging in the U.S biotechnology sector, so why are investors still fearful about committing? Noël Brown, Head of U.S. Biotechnology Investment Banking at RBC Capital Markets, is joined by fund founders Craig Gordon, MD, CEO and CIO at GordonMD® Global Investments LP and Srini Akkaraju, MD, PhD, Managing Partner at Samsara BioCapital, to analyze the prospects for a full return of capital to the sector.…

1
Former Investor Who Chose Broadcasting Over Biotech ETFs 11:46

36 weeks тому11:46

11:46

1
Can AI Solve Molecule Mysteries that will Unlock Simpler Drug Discovery? 33:55

40 weeks тому33:55

33:55

The hardest parts of drug discovery will be vastly simplified if the mysteries of molecules and proteins can be cracked. That may be beyond human capabilities – but AI is working hard on it. In this episode of RBC’s Pathfinders in Biopharma, Noël Brown is joined by Clarissa Desjardins, CEO of Congruence, and Laksh Aithani, CEO and Co-founder of Charm Therapeutics, to discuss how far the tech can take us.…

1
Shots-on-Goal Licensing Company Aims for Breakthroughs 13:52

46 weeks тому13:52

13:52

A very special breed of animals is helping biotech and pharma companies in the quest for new human therapeutics. CFO Kurt Gustafson joins Pathfinders in Biopharma to explain the technologies behind OmniAb’s business model.

1
Why Biopharma Needs to Tell Better Stories on Novel Drugs 15:31

47 weeks тому15:31

15:31

Ronald Martell is a serial entrepreneur and biopharma veteran whose record includes the launch of Herceptin. He continues his mission to bring new drugs to patients with unmet medical needs. The CEO of Jasper Therapeutics explains his ambitions for his company’s new antibody therapy and for the future of the industry.…

1
Venture capital velocity: What’s driving renewed momentum in biotech? 35:03

48 weeks тому35:03

35:03

In biotech, a recovery is already well underway. Expected interest rate cuts and improving valuations across public and private markets are creating a compelling environment for deals, entrances, exits, and trades to take shape. In this episode, biotech venture capital experts assess the sector’s sharper focus on funding fundamental science, evolving deal structures, including the return of reverse mergers and dual-track processes, and the key therapeutic modalities that are driving momentum in the market. Hear from Andrew Aherrera, Partner at Panacea Venture; Jeni Lee, Partner at Pivotal Life Sciences; Regina Salvat, Principal at Sofinnova; and Noël Brown, Head of US Biotechnology Investment Banking at RBC Capital Markets, as they share their fresh perspectives on the dynamic forces propelling the biotech industry forward.…

1
Pharma Understands Phase One Data – But Does the Market? 25:30

50 weeks тому25:30

25:30

Public biotech Pyxis Oncology is taking forward its innovative work on ADCs. President and CEO, Lara Sullivan, explains the company’s journey to find the right investors, and why she believes the markets still have some learning to do when analyzing data from early-stage studies.

1
Davern Capital sees GLP-1 Opportunities Beyond Obesity 9:39

51 weeks тому9:39

9:39

Davern Capital’s founder, Elie Kobrin, approaches the biopharma market from a long/short perspective – but as a former doctor, he also speaks the language of medicine. He explains the fund’s approach and offers insights on hot topics in the current market.

1
Betting on Healthcare’s Future Hits – and Misses 14:47

52 weeks тому14:47

14:47

As a healthcare-focused, market-neutral investor, Vince Aita stays close to new product developments with a view to identifying future successes and failures. At RBC’s Global Healthcare Conference, he offered his insights on everything from the future of obesity innovation to the impact of the IRA.

1
Innovation and an Aging Population Drive MedTech 16:01

1 year тому16:01

16:01

The MedTech sector continues to grow in the U.S. as innovation in patient treatments and delivery meets increased demand from an aging population. Medical technology analyst Shagun Singh assesses key data points from the RBC Capital Markets’ Doctor Days events, looking at how the healthcare sector can empower investors to position themselves for future growth.…

1
Biopharma Investors See Opportunities in Targeted Treatments and Gene Editing 20:39

1 year тому20:39

20:39

Personalized, targeted drugs and gene therapies are still at the forefront of medical innovation, as we discovered at RBC Capital Markets annual Doctor Days meetings. These insightful forums bring together key opinion leader clinicians and researchers from various therapeutic fields with institutional investors to discuss where opportunities lie, the next big breakthroughs, and the most novel drug therapies. Brian Abrahams, Gregory Renza, and Luca Issi join the podcast to discuss findings from the meetings.…

1
Biotech with a Mission to Target Unmet Cancer Needs 13:37

1 year тому13:37

13:37

IDEAYA’s drug development programs center around addressing unmet patient needs. Its founder tells Pathfinders in Biopharma why he believes there has never been more opportunity for breakthroughs in the fight against cancer.

1
The M&A Pool Set to Accelerate Biotech Innovation 13:51

1 year тому13:51

13:51

Q1 2024 saw a handful of IPOs in the biotech sector, and mounting excitement over novel treatments. But there are less obvious trends in play, including a shift in focus by potential buyers in pharma. RBC’s biotech investment banking team analyzes deal activity in the year to date and what it signals for the sector’s future.…

Pathfinders in Biopharma

1
How PIPEs finally unblocked biotech’s funding flows 17:36

1 year тому17:36

17:36

The first quarter of 2024 has seen biotech’s funding drought broken, largely through private investment in public equity (PIPE) deals. In this episode of Pathfinders in Biopharma, three members of RBC’s biotech investment banking team look at the impact of PIPEs’ success on the sector and consider how long it can last – and why it has not been universally welcomed.…

Pathfinders in Biopharma

1
Disruptive Forces in Healthcare: Why HCIT is finally set to bounce back 12:58

1 year тому12:58

12:58

U.S. healthcare desperately needs to cut costs and improve outcomes. There is no single solution, but three disruptive forces in the digital health space are speeding change – and adding up to a healthy outlook for HCIT. Sean Dodge, Healthcare Technology Analyst, joins the podcast to unpack some of his predictions on the most impactful forces affecting healthcare.…

Pathfinders in Biopharma

1
Will the Biotech Rebound Run into Pricing Policy Obstacles? 13:25

1 year тому13:25

13:25

Drug pricing is already an issue in the U.S. election campaign. Brian Abrahams, MD and Head of Biotech Research at RBC Capital Markets joins the Pathfinders in Biopharma podcast to consider how this, together with other policy developments in the U.S. and worldwide, might affect a resurgent biotech sector.…

Pathfinders in Biopharma

1
Few IPOs but plenty of follow-on for biotech in 2023 23:35

1 year тому23:35

23:35

After a year of stark contrasts in the public and private equity markets for healthcare, 2024 is shaping up to be another mixed outlook. While biotech continues to bolster the market, albeit more in follow-on offerings than IPOs, and HCIT and healthcare services have tailwinds, the medtech and value-based care subsectors have challenges as well as opportunities. Join our Co-Heads of Healthcare Equity Markets for their insights into the year ahead.…

Pathfinders in Biopharma

1
U.S. Outlook: Will the US economy achieve a soft landing in 2024? 26:28

1 year тому26:28

26:28

As the U.S. economy shows positive signs for growth, inflation, and interest rates in 2024, RBC Capital Markets’ RBC Capital Markets’ Michael Reid, Blake Gwinn, Vito Sperduto and Larry Grafstein analyze the challenges posed by consumer spending, political gridlock, and quantitative tightening. This episode was originally published on RBC's Strategic Alternatives podcast.…

Pathfinders in Biopharma

1
Raising Venture Capital: A New Playbook for A New Era in Biotech 36:19

2 years тому36:19

36:19

In an era characterized by macro headwinds and profound market volatility, the biotech industry continues to raise capital to fuel drug development, clinical trials, and innovation. Capital raising in challenging markets comes with additional risks, leading venture capital firms and crossover investors to identify creative, unconventional deal structures and strategies that are redefining the biotech investment landscape. Join Chen Yu, Founder & Managing Partner at TCGX, Matthew Young, Managing Director at Longitude Capital, Arsani William, CIO & Managing Partner at Logos Capital, and RBC’s Noël Brown, Head of US Biotechnology Investment Banking, for a roundtable discussion exploring how investors across the biotech ecosystem are navigating market complexity to put dollars to work creatively to manage risks, maximize rewards, and stimulate growth.…

Pathfinders in Biopharma

1
ECM: Robust End to Year, Despite Previous Volatility 31:24

2 years тому31:24

31:24

As RBC Capital Markets looks forward to a robust end to the year, John Hoffman and Jason Levitz, Co-Heads of Healthcare Equity Capital Markets explore how the firms who succeed in an especially dynamic market will be those willing to embrace new ways of thinking about unlocking value.

Pathfinders in Biopharma

1
Biotech Halftime Report: A Winding Road Ahead 17:26

2 years тому17:26

17:26

Join Head of US Capital Markets Research, Mark Odendahl and biotech analysts Brian Abrahams and Gregory Renza, as they explore the dynamic biotech sector landscape in H2 2023. This episode was originally broadcast on Industries in Motion, the RBC podcast.

Pathfinders in Biopharma

1
The Urgent Need to Address the Youth Mental Health Landscape 28:06

2 years тому28:06

28:06

U.S. soccer legends and World Cup champions Briana Scurry and Dr. Sara Hess joined Andrew Callaway, Global Head of Healthcare Investment Banking at RBC Capital Markets, at this year’s RBC Global Healthcare Conference.

Pathfinders in Biopharma

1
Website Traffic Reveals Biopharma Sales Trends 10:39

2 years тому10:39

10:39

A new RBC ElementsTM report, “Insights from the BioWeb,” looks at the predictive potential of website traffic as a means to uncover underappreciated market trends and sales insights. Mark Odendahl, Head of US Capital Markets Research, is joined by Brian Abrahams, Head of Biotechnology at RBC Capital Markets, to discuss the report’s findings.…

Pathfinders in Biopharma

1
When to Call it Quits: VCs Making Tough Decisions in a Tough Market 32:02

2 years тому32:02

32:02

While the public biotech markets remain volatile, VCs continue to raise new funds. Are we witnessing a renaissance in the private capital markets? The bankruptcy rate of biotechs is historically among the lowest of US publicly traded companies, however, companies are failing and there is still a widely held belief that too many biotech companies are in existence today. What are the hallmarks of companies that will not make it, and when does it make sense to ‘call it’ or divest? In this episode of Pathfinders in Biopharma, hear from Jerel Davis, Managing Director at Versant Ventures, Otello Stampacchia, Founder & Managing Director at Omega Funds, Simeon George, CEO & Managing Partner at SR One and RBC’s Noël Brown, Head of US Biotechnology Investment Banking, for a roundtable discussion on navigating the path to growth.…

Pathfinders in Biopharma

1
How Biotech M&A is Redefining the Strategic Landscape 25:53

2 years тому25:53

25:53

Given current macro and regulatory headwinds, determining the optimal time to sell a biotech company is a multifaceted decision that requires careful consideration of several key factors. Hear from industry veterans Ted Love, Marc de Garidel, and Abbas Kazimi who share their insights on a new era of M&A in a panel moderated by RBC Capital Markets Analysts Dr. Brian Abrahams, Dr. Luca Issi and Dr. Gregory Renza.…

Pathfinders in Biopharma

1
Healthcare Should Get Ready for ‘Fast and Furious’ M&A 26:06

2 years тому26:06

26:06

Hear from Vito Sperduto, RBC’s Co-Head of Global M&A, and his panel of RBC Capital Markets’ expert bankers on how large healthcare firms with strong balance sheets are putting cash to work — driving a ‘fast and furious’ surge of M&A activity in the second half of the year and into 2024. Learn why healthcare momentum is building and how smaller deals are shaping M&A across the sector in the latest episode of Pathfinders in Biopharma. This podcast also features insights from Andrew ‘Cal’ Callaway, Global Head of Healthcare Investment Banking, Ahmed Attia, Managing Director of Healthcare M&A, and Co-Head of US M&A, David Levin. This podcast episode was originally broadcast on Strategic Alternatives, the RBC M&A podcast.…

Pathfinders in Biopharma

1
Innovation and Growth: Key Ingredients to Healthcare M&A 24:18

2 years тому24:18

24:18

Compressed valuations, heightened CEO confidence, and the desire to accelerate top-line growth and scale innovation are the key factors driving healthcare M&A in 2023. As deal activity starts to accelerate, our banking experts are asking, what’s next for the sector? Listen to Pathfinders in Biopharma to find out. This episode features insights from Vito Sperduto, Co-Head of Global M&A, Andrew ‘Cal’ Callaway, Global Head of Healthcare Investment Banking, Ahmed Attia, Managing Director of Healthcare M&A, and David Levin, Co-Head of US M&A at RBC Capital Markets. This episode was originally broadcast on Strategic Alternatives, the RBC M&A podcast.…

Pathfinders in Biopharma

1
Biotech M&A Booms, But Have Buyouts Reached a Tipping Point? 17:04

2 years тому17:04